Since Cleveland BioLabs Inc. (NASDAQ:CBLI) and Molecular Templates Inc. (NASDAQ:MTEM) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation of both companies.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cleveland BioLabs Inc.||2||13.75||N/A||-0.29||0.00|
|Molecular Templates Inc.||7||8.67||N/A||-0.90||0.00|
Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Cleveland BioLabs Inc. and Molecular Templates Inc.
Table 2 demonstrates the return on equity, return on assets and net margins of Cleveland BioLabs Inc. and Molecular Templates Inc.
|Net Margins||Return on Equity||Return on Assets|
|Cleveland BioLabs Inc.||0.00%||282.5%||-61.9%|
|Molecular Templates Inc.||0.00%||-30.4%||-21.7%|
Volatility and Risk
Cleveland BioLabs Inc. has a 0.64 beta, while its volatility is 36.00%, thus making it less volatile than Standard and Poor’s 500. Molecular Templates Inc.’s 173.00% more volatile than Standard and Poor’s 500 volatility due to the company’s 2.73 beta.
The Current Ratio and a Quick Ratio of Cleveland BioLabs Inc. are 3.7 and 3.7. Competitively, Molecular Templates Inc. has 3.2 and 3.2 for Current and Quick Ratio. Cleveland BioLabs Inc.’s better ability to pay short and long-term obligations than Molecular Templates Inc.
Insider & Institutional Ownership
Cleveland BioLabs Inc. and Molecular Templates Inc. has shares held by institutional investors as follows: 5.2% and 72.2%. About 58.14% of Cleveland BioLabs Inc.’s share are held by insiders. Comparatively, Molecular Templates Inc. has 12.75% of it’s share held by insiders.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Cleveland BioLabs Inc.||6.38%||-1.87%||9.03%||11.35%||-36.08%||55.45%|
|Molecular Templates Inc.||-8.75%||-22.34%||-8.88%||47.64%||32.46%||62.62%|
For the past year Cleveland BioLabs Inc. was less bullish than Molecular Templates Inc.
Cleveland BioLabs Inc. beats on 4 of the 7 factors Molecular Templates Inc.
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation. The companyÂ’s advanced product candidate is entolimod, a Toll-like receptor 5 (TLR5) agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. In addition, the company develops CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with The Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.